Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Prignano

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|November 6, 2014
PSOCUBE, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithmD Linder, G Altomare, S Amato, et al.
Clinical and Experimental Immunology|August 30, 2016
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactionsA Vultaggio, G Petroni, S Pratesi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 16, 2016
Soccer helps in controlling the development of psoriasis in Italian second league playersM Megna, A Lobasso, M Napolitano, et al.
The British Journal of Dermatology|September 7, 2018
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registryP Gisondi, L Bianchi, P Calzavara-Pinton, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2020
Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscoreA V Marzano, A Chiricozzi, G Giovanardi, et al.
The Journal of Dermatological Treatment|May 1, 2020
Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION studyF Marsili, M Travaglini, G Stinco, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 1, 2017
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasisP Gisondi, G Altomare, F Ayala, et al.
Expert Review of Clinical Immunology|May 19, 2020
TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasisPaolo Gisondi, Davide Geat, Andrea Conti, et al.
Archives of Dermatological Research|May 25, 2024
Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areasA Michelucci, F Manzo Margiotta, A Cartocci, et al.
The British Journal of Dermatology|December 23, 2018
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experienceA Conti, F Peccerillo, P Amerio, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Journal of the European Academy of Dermatology and Venereology : JEADV|November 6, 2014
PSOCUBE, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithmD Linder, G Altomare, S Amato, et al.
Clinical and Experimental Immunology|August 30, 2016
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactionsA Vultaggio, G Petroni, S Pratesi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 16, 2016
Soccer helps in controlling the development of psoriasis in Italian second league playersM Megna, A Lobasso, M Napolitano, et al.
The British Journal of Dermatology|September 7, 2018
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registryP Gisondi, L Bianchi, P Calzavara-Pinton, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2020
Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscoreA V Marzano, A Chiricozzi, G Giovanardi, et al.
The Journal of Dermatological Treatment|May 1, 2020
Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION studyF Marsili, M Travaglini, G Stinco, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 1, 2017
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasisP Gisondi, G Altomare, F Ayala, et al.
Expert Review of Clinical Immunology|May 19, 2020
TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasisPaolo Gisondi, Davide Geat, Andrea Conti, et al.
Archives of Dermatological Research|May 25, 2024
Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areasA Michelucci, F Manzo Margiotta, A Cartocci, et al.
The British Journal of Dermatology|December 23, 2018
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experienceA Conti, F Peccerillo, P Amerio, et al.
Pageof 7